Navigation Links
Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
Date:9/13/2011

MOUNTAIN VIEW, Calif., Sept. 13, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today presented positive results from the avanafil phase 3 study in diabetics.  In the REVIVE-Diabetes study (TA-302), male diabetics receiving avanafil had significant improvement in erectile function.  Dr. Irwin Goldstein, Director of Sexual Medicine at Alvarado Hospital, San Diego, CA, presented the results of the study during the poster session at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting in Lisbon, Portugal.  Results of the study have been previously reported, but this was the first public European presentation of avanafil safety and efficacy data in diabetic patients.  

The study included 390 patients with type 1 and type 2 diabetes treated over 12 weeks with avanafil 100mg, 200mg, or placebo.  Diabetics are disproportionately affected by erectile dysfunction (ED), which can worsen with increased duration of disease, and these patients are often considered less responsive to therapy.

This study population consisted of men with an average age of 58 years and a mean duration of diabetes of eleven years and ED of five to six years.  The majority were type 2 diabetics, with approximately 10% having type 1 diabetes.  Avanafil was associated with significant improvements in erectile function relative to placebo (calculated as least-squares (LS) mean change from baseline for all of the co-primary endpoints (P< 0.0001)).  Subgroup analyses demonstrated that improvements in the percentage of successful intercourse attempts with avanafil 100 mg and avanafil 200 mg were observed regardless of diabetes classification (type 1 or 2), duration of diabetes, or baseline ED severity (P<0.05).  Successful intercourse was achieved in some subjects in 15 minutes or less after dosing with avanafil.  S
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium
2. Initial Trial of Sanarias Malaria Vaccine Yields Positive Results
3. Metabolic Solutions Development Company Reports Positive Top-Line Results From Phase 2a Study of Its Second Compound to Treat Type 2 Diabetes
4. Auxilium Pharmaceuticals Announces Positive Data from Commercial Patient Chart Review in E-posters at ASSH Meeting
5. Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study
6. Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
7. BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence
8. Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
9. Curemark Reports Positive Results for Novel Compound CM-182 in Amphetamine Induced Hyperactivity
10. Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter
11. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 3SBio Inc., ("3SBio") a leading biotechnology ... focusing on researching, developing, manufacturing and marketing biopharmaceutical ... an exclusive license agreement with JenKem Technology Co., ... in Mainland China of PEG-irinotecan, a long-acting polymer-drug ... over-expressed in many solid tumors, including colorectal, ovarian, ...
(Date:9/16/2014)... OAKLAND, Calif. , Sept. 16, 2014  Chairman ... that Richard (Dick) Daniels will assume the ... Foundation Hospitals and Health Plan, Inc., effective immediately. ... developing and implementing technological advancements that advance the high-quality ... members," Tyson said. " Dick Daniels has extensive ...
(Date:9/16/2014)... Endo International plc (NASDAQ: ENDP ) (TSX: ENL) ... all of the outstanding shares of Auxilium Pharmaceuticals, Inc. (NASDAQ: ... $28.10 in a cash and stock transaction valued at $2.2 ... to Auxilium,s closing price on September 16, 2014 and a ... for the previous 30 days.  Under the terms of the ...
Breaking Medicine Technology:3SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals Name Interim Chief Information Officer 2Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 2Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 3Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 4Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 5Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 6Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 7
... KineMed Inc., a,pathway-based drug discovery and development ... of an investigational agent,to regenerate nerve cells in ... cognition and mood. The agent, part of a ... a behavioral test in a,preclinical model. The findings ...
... am ET, BEDMINSTER, N.J., Oct. 11 ... top-line results from,the company,s Phase 3 study of ... 83 patients with short bowel,syndrome (SBS) received either ... dose (0.10 mg/kg/day) or placebo. The,clinical efficacy endpoint ...
Cached Medicine Technology:KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 2Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 4Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 5Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 6Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 7
(Date:9/17/2014)... Diabetes currently has no cure. According to an ... made several breakthroughs in search for a ... indicates that cure for diabetes is still many years ... forward-thinking entrepreneurs and health professionals who made strides in ... Kenneth Pullman is one of the individuals with genuine ...
(Date:9/17/2014)... 2014 Skin management experts™ at ... of the first in the USA to introduce a ... to minimize the appearance of vertical chest lines and ... with the first FDA-cleared ultrasound based facial procedure to ... have expanded their brand into tightening and smoothing the ...
(Date:9/17/2014)... AURORA, Colo. (PRWEB) September 17, 2014 ... American Sentinel University offers tips to health IT professionals ... , A recent study by HIMSS shows demand ... high and a candidate’s skill set is the differentiating ... is that of an IT professional that has clinical ...
(Date:9/17/2014)... 2014 Lee Berman, a seasoned veteran ... appearing on The Balancing Act® airing on Lifetime Television®. ... The segment will premiere on September 19 and re-air ... airing on Lifetime Television®' with show host Julie Moran. ... for over a decade and is the Director of ...
(Date:9/17/2014)... Kingston, NY (PRWEB) September 17, 2014 ... style of wellness to the lineup at Techmanity, a ... as “the next generation of tech events,” Techmanity will ... Voom is excited to join the ranks of Cisco, ... this first ever Silicon Valley Technology Conference. , Voom ...
Breaking Medicine News(10 mins):Health News:Discover a Safe and Effective Treatment for Diabetes with The Diabetes Protocol – Vinamy 2Health News:FACE Skincare Medical Wellness Debuts Ultherapy Décolletage Treatment 2Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 2Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 3Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 4Health News:Lee Berman Will Appear On The Balancing Act® airing on Lifetime Television® 2Health News:Health and Wellness Startup Voom Announces Sponsorship at Techmanity 2
... over-the-counter drug might reverse genetic process that leads to ... -- Researchers may have found an easy way to ... stages, as well as a way to reverse the ... over-the-counter drug. , "It,s incredibly, incredibly exciting," said ...
... the number of older Americans who delay retirement is likely ... a trend that should help ease the financial challenges facing ... Corporation study. While government projections suggest the number of ... the coming decade, RAND researchers say a more likely scenario ...
... Be ... , ... Each year, millions of Americans wait to file their federal income tax returns until the ... fast approaching, leading sleep advice web site SleepBetter.org is offering some tips to ...
... ... released version 4.3 of Replay, the award-winning, next generation backup and disaster recovery software ... Reston, ... of Replay, the award-winning, next generation backup and disaster recovery software solution. Because ...
... a condition in which the eyes turn outward while looking ... and is less common than esotropia, where the eyes turn ... of the American Journal of Ophthalmology , researchers from ... patients with intermittent exotropia over a 20-year period and found ...
... ... Suite of International Hosting and Managed Services. , ... Mississauga, Ontario (PRWEB) April 7, 2010 ... announced that it has launched the first international, multi-infrastructure cloud computing service ...
Cached Medicine News:Health News:Simple Test May Spot Early Lung Cancer 2Health News:Simple Test May Spot Early Lung Cancer 3Health News:Delayed retirement among Americans may bolster future of Social Security and Medicare, study finds 2Health News:Delayed retirement among Americans may bolster future of Social Security and Medicare, study finds 3Health News:Last-Minute Tax Tip: Get a Good Night's Sleep 2Health News:Last-Minute Tax Tip: Get a Good Night's Sleep 3Health News:De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V 2Health News:De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V 3Health News:90 percent of children with intermittent exotropia will become nearsighted by 20 years of age 2Health News:CentriLogic Launches First Canadian-Based Distributed Cloud Computing Service 2Health News:CentriLogic Launches First Canadian-Based Distributed Cloud Computing Service 3
For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
Medicine Products: